Actelion Defends PAH Franchise With Generics And Second-Generation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
With patent erosion starting for Tracleer, its largest-selling product, Actelion outlines further details of its short- and medium-term strategy to reduce its reliance on the billion-dollar PAH therapy.
You may also be interested in...
European Pharma In Cost-Cutting Mode: Actelion Axes 135 Positions, Sanofi Aims At French R&D Consolidation
Europe's leading biotech Actelion plans to cut 5% of its workforce, while Sanofi considers a major overhaul of its R&D sites in France, as competitive pressures and the European debt crisis continue.
Actelion's Macitentan Meets Primary Endpoint In Pivotal SERAPHIN Study, Approval Filings Expected In Fourth Quarter
Swiss biotech Actelion expects to submit its next-generation PAH therapy macitentan for approval in the fourth quarter of this year, giving it time to replace current top-selling product Tracleer before that product loses patent protection in 2015.
Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning
REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.